Ascending single and multiple oral doses of chemokine receptor 1 antagonist administered to healthy subjects

Phase 1

Completed

• Conditions: Rheumatoid arthritis; Inflammatory and Immune System - Rheumatoid arthritis

• Registration Number: ACTRN12609000788279
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-09-10
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

Healthy subjects (men and women) having Body Mass Index (BMI) between 18 and 32 kg/m2
Women must not be of childbearing potential (i.e., who are postmenopausal or surgically sterile).

Exclusion Criteria

Any significant acute or chronic medical illness.
Subjects at risk for tuberculosis (TB).
Evidence of organ dysfunction or any clinically significant deviation from normal.
Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) greater than 1.25 x upper normal limit (UNL) at screening.

Study & Design

• Study Type: Interventional
• Study Design: Not specified